Kansas is currently home to 923 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Wichita, Kansas City, Overland Park and Topeka. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Microbiome in Immunotherapy naïve NSCLC Patients Receiving PD-1/L1 Blockade (MIP_NSCLC)
NCT04636775
Recruiting
This phase IV study is hoping to determine if examining the microbiome in non-small cell lung cancer, immunotherapy naive participants can predict the effectiveness of immunotherapy treatment as well as determine ahead of time adverse events and their severity. In addition, the investigator will look into microbiome changing modifiers.
Gender:
All
Ages:
18 years and above
Trial Updated:
12/08/2023
Locations: The University of Kansas Cancer Center (KUCC), Fairway, Kansas
Conditions: NSCLC Stage IV, NSCLC, Recurrent
Register for Updates
Comparing Hypo-fractionated Intensity- Modulated Radiation Therapy to Standard- Fractionated IMRT Along With Chemotherapy and Immunotherapy for Non-Small Cell Lung Cancer
NCT04992780
Recruiting
The hypothesis for this study is that hypofractionated IMRT to 62.5 Gy in 25 fractions (2.5 Gy/fraction) with concurrent carboplatin and paclitaxel, followed by maintenance durvalumab will improve locoregional control at 18 months by 10% compared to standard-fractionated chemo-IMRT/durvalumab. A modest improvement in locoregional control (LRC) was selected as a target which could merit further study of this hypofractionated IMRT regimen in a Phase III trial
Gender:
All
Ages:
18 years and above
Trial Updated:
12/05/2023
Locations: The University of Kansas Cancer Center, Westwood Campus, Kansas City, Kansas
Conditions: Non Small Cell Lung Cancer Stage
Register for Updates
PREHEVBRIO Pregnancy Outcomes Registry
NCT06097312
Recruiting
The registry is an observational surveillance program designed to recruit and encourage participation of women who were exposed to PREHEVBRIO® hepatitis B vaccine during pregnancy and to collect and analyze information related to post-exposure pregnancy and fetal and neonatal outcomes. The objective of the Registry is to monitor and evaluate all received reports of PREHEVBRIO® vaccine exposure within 28 days prior to conception or at any time during pregnancy and delivery, as well as maternal,... Read More
Gender:
Female
Ages:
All
Trial Updated:
11/30/2023
Locations: ProPharma, Recruiting Nationwide, Overland Park, Kansas
Conditions: Vaccine Exposure During Pregnancy
Register for Updates
A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)
NCT04951219
Recruiting
A 52-Week, Multi-center, Open-label, Active Treatment Extension Study to Evaluate Safety and Tolerability of Once Daily, Oral Administration of Resmetirom (MGL-3196)
Gender:
All
Ages:
18 years and above
Trial Updated:
11/28/2023
Locations: Kansas Medical Clinic - Gastroenterology, Topeka, Kansas
Conditions: Non-Alcoholic Fatty Liver Disease
Register for Updates
Total30 for Astigmatism Contact Lenses
NCT06052046
Recruiting
Determine if Total30 for Astigmatism contact lenses (CLs) provide a comfortable wearing experience all day. CL discomfort affects most CL wearers with discomfort consistently topping the reasons why established CL wearers drop out of CLs. In fact, studies have consistently found that the frequency of CL dropout is around 20% with this dropout frequency staying relatively stable over the past 20 plus years. This static frequency of CL dropout is surprising since there have been a number of dramat... Read More
Gender:
All
Ages:
Between 18 years and 45 years
Trial Updated:
11/21/2023
Locations: Kannarr Eye Care, Pittsburg, Kansas
Conditions: Contact Lens Complication, Astigmatism, Refractive Errors
Register for Updates
Connect® Lymphoma Disease Registry: A US-Based Prospective Observational Cohort Study
NCT04982471
Recruiting
The Connect® Lymphoma Disease Registry is a US-based, multicenter, prospective observational (non-interventional) cohort study designed to collect real-world, participant-level data longitudinally in participants diagnosed with various subtypes of non-Hodgkin lymphoma (NHL).
Gender:
All
Ages:
18 years and above
Trial Updated:
11/15/2023
Locations: Cotton O'Neil Clinical Research, Hematology and Oncology, Topeka, Kansas
Conditions: Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular
Register for Updates
Comparative Pharmacokinetic Study of Three Abatacept Products in Male Normal Healthy Volunteers by the Subcutaneous Route
NCT06126042
Recruiting
This is a randomised, double-blind, single dose, parallel groups study to compare the PK, immunogenicity, and safety of 3 abatacept products (DRL_AB, RP and RMP) in male NHV.
Gender:
Male
Ages:
Between 18 years and 50 years
Trial Updated:
11/08/2023
Locations: ICON, plc., Lenexa, Kansas
Conditions: Rheumatoid Arthritis
Register for Updates
Ipatasertib and Docetaxel in Metastatic NSCLC Patients Who Have Failed 1st Line Immunotherapy
NCT04467801
Recruiting
For metastatic/advanced NSCLC patients who do not have targetable mutations, either immunotherapy targeting the programmed death-1 and its ligand (PD-1/L1) pathway alone or in combination with platinum doublet chemotherapy is now a standard of care. However, still about half of the patients do not benefit due to treatment resistance. It is therefore critically important to find novel therapies and combinations to benefit patients who have failed or are intolerant to 1st line immunotherapy. This... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
11/02/2023
Locations: The University of Kansas Cancer Center (KUCC), Fairway, Kansas
Conditions: NSCLC Stage IV, NSCLC Stage IIIB
Register for Updates
Portico Re-sheathable Transcatheter Aortic Valve System US IDE Trial
NCT02000115
Recruiting
The objective of the PORTICO pivotal IDE trial is to evaluate the safety and effectiveness of the St Jude Medical (SJM) Portico Transcatheter Heart Valve and Delivery Systems (Portico) in the treatment of severe symptomatic aortic stenosis via transfemoral and alternative delivery methods in high risk and extreme risk patients.
Gender:
All
Ages:
21 years and above
Trial Updated:
10/24/2023
Locations: Cardiovascular Research Institute of Kansas, Wichita, Kansas
Conditions: Aortic Valve Stenosis
Register for Updates
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
NCT04715022
Recruiting
The main purpose of research is to examine and understanding the development of hypertension in obese adults with insulin resistance. Findings from our studies will identify unique mechanisms that can be targeted to limit increases in vascular dysfunction and reduce the excessively high prevalence of hypertension and risk for cardiovascular disease (CVD). This study is testing the health of the blood vessels and the activity of the nerves that control the blood vessels in adults with insulin re... Read More
Gender:
All
Ages:
Between 35 years and 65 years
Trial Updated:
10/20/2023
Locations: University of Kansas Medical Center, Kansas City, Kansas
Conditions: Hypertension, Cardiovascular Diseases
Register for Updates
Tigulixostat, Phase 3 Study, Allopurinol Controlled in Gout Patients
NCT05586971
Recruiting
The aim of this 12-month randomized multi-regional double-blind parallel group allopurinol and placebo-controlled phase 3 study is to assess the efficacy and safety of three different doses of Tigulixostat in gout patients with hyperuricemia.
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
10/17/2023
Locations: Women's & Family Care LLC, dba GTC Research, Shawnee Mission, Kansas
Conditions: Gout, Hyperuricemia, Gout Flare, Tophi
Register for Updates
Efficacy Rate of Unipolar Polarity Switch for Lesion Assessment in Pulmonary Vein Isolation
NCT05464537
Recruiting
The technique of intraprocedural electrogram morphology as a measure of lesion effectiveness in an attempt to achieve durable PVI, clearly led to shortened procedural time, radiation exposure, and superiority in outcomes, with the implementation of a reproducible, readily available intraprocedural tool that can be applied universally.
Gender:
All
Ages:
18 years and above
Trial Updated:
10/17/2023
Locations: Kansas City Heart Rhythm Institute, Overland Park, Kansas
Conditions: Atrial Fibrillation
Register for Updates